Investigating the feasibility of stem cell enrichment mediated by immobilized selectins.
Hematopoietic stem cell therapy is used to treat both malignant and non-malignant diseases, and enrichment of the hematopoietic stem and progenitor cells (HSPCs) has the potential to reduce the likelihood of graft vs host disease or relapse, potentially fatal complications associated with the therapy. Current commercial HSPC isolation technologies rely solely on the CD34 surface marker, and while they have proven to be invaluable, they can be time-consuming with variable recoveries reported. We propose that selectin-mediated enrichment could prove to be a quick and effective method for recovering HSPCs from adult bone marrow (ABM) on the basis of differences in rolling velocities and independently of CD34 expression. Purified CD34+ ABM cells and the unselected CD34- ABM cells were perfused over immobilized P-, E-, and L-selectin-IgG at physiologic wall shear stresses, and rolling velocities and cell retention data were collected. CD34+ ABM cells generally exhibited lower rolling velocities and higher retention than the unselected CD34- ABM cells on all three selectins. For initial CD34+ ABM cell concentrations ranging from 1% to 5%, we predict an increase in purity ranging from 5.2% to 36.1%, depending on the selectin used. Additionally, selectin-mediated cell enrichment is not limited to subsets of cells with inherent differences in rolling velocities. CD34+ KG1a cells and CD34- HL60 cells exhibited nearly identical rolling velocities on immobilized P-selectin-IgG over the entire range of shear stresses studied. However, when anti-CD34 antibody was co-immobilized with the P-selectin-IgG, the rolling velocity of the CD34+ KG1a cells was significantly reduced, making selectin-mediated cell enrichment a feasible option. Optimal cell enrichment in immobilized selectin surfaces can be achieved within 10 min, much faster than most current commercially available systems.
Charles
Nichola
N
Department of Biomedical Engineering, University of Rochester, Rochester, New York, USA.
Liesveld
Jane L
JL
King
Michael R
MR
D018952:Antigens, CD34 / Q000032:analysis; D002469:Cell Separation / Q000379:methods*; D018922:HL-60 Cells; D006412:Hematopoietic Stem Cells / Q000166:cytology*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D036904:Leukocyte Rolling; D019007:P-Selectin / Q000276:immunology
D018952:Antigens, CD34; D007074:Immunoglobulin G; D019007:P-Selectin